



ITW

Attorney Docket No. VPI/02-114 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/694,534
Confirmation No.: 1905
Filing Date: October 27, 2003
Examiner: Charanjit Aulakh
Group Art Unit: 1625
Applicants: Alex Aronov et al.
For: INDAZOLINONE COMPOSITIONS USEFUL AS KINASE
INHIBITORS

October 13, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copy(ies) of references Citation No(s). A1; B1-B16; C1-C4 are attached.
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).
- ☒ A copy of the International Search Report received in the corresponding PCT Application No. PCT/US03/34065 is attached herewith.

- (b) ☐ No fee is believed due because:

- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

Applicants: Alex Aronov et al.
Application No.: 10/694,534

- (c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☒ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ In accordance with 37 C.F.R. § 1.98(a)(3)(i), references B5-B7, B9 and B14-16 are relevant because they were cited in the International Search Report of corresponding PCT application number PCT/US03/34065.

Applicants: Alex Aronov et al.
Application No.: 10/694,534



The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,

Karen E. Brown
Karen E. Brown, Reg. No. 43,866
Attorney/Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Mail Stop: Amendment, P.O. Box 1450, Alexandria, VA 22313-1450 on 10-13-05

Lisa M. Romano
Lisa M. Romano

10-13-05
Date of Signature

Our Docket No.: VPI/02-114 US



Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On October 13, 2005
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. Copy of International Search Report (14 pgs.) ;
3. PTO-1449 Form (1 page, in duplicate);
4. Cited References (A1; B1-B16 ; C1-C4); and
5. Return Postcard Receipt.

Signature

Lisa M. Romano
Typed or printed name of person signing Certificate



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/694,534
	Filing Date	October 27, 2003
	First Named Inventor	Alex Aronov et al.
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-114 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	3,816,121	06/11/1974	Shiba et al.	96	97	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO 03/068743 A1	Astrazeneca AB	August 21, 2003		
	B2	WO 03/063797 A2	Bristol-Myers Squibb Company	August 7, 2003		
	B3	WO 03/040096 A2	Elan Pharmaceuticals, Inc. et al.	May 15, 2003		
	B4	WO 03/024962 A1	Astrazeneca AB	March 27, 2003		
	B5	EP 0 075 808 A2	Bayer AG	April 6, 1983		X
	B6	DE 25 33 958 A1	Hoechst AG	February 17, 1977		X
	B7	FR 1 516 610	Ferrania SPA	March 8, 1968		X
	B8	EP 1 199 306 A1	Banyu Pharmaceutical Co. Ltd.	April 24, 2002		
	B9	WO 03/078402 A1	Aventis Pharma S.A.	September 25, 2003		X
	B10	WO 98/24771 A1	Fujisawa Pharmaceutical Co., Ltd.	June 11, 1998		
	B11	EP 1 256 574 A1	Kirin Beer Kabushiki Kaisha	November 13, 2002		
	B12	EP 1 380 576 A1	Eisai Co., Ltd.	January 14, 2004		
	B13	WO 02/062795	Mitsubishi Pharma Corporation	August 15, 2002		
	B14	JP 2001-354511	Fuji Photo Fillm Co., Ltd.	December 25, 2001		X
	B15	JP 3-179345	Konica Co.	August 5, 1991		X
	B16	JP 3-150560	Konica Co.	June 26, 1991		X

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	File Chemical Abstracts, STN Caesar accession number: 1189, AN 52:25500.
	C2	File Chemical Abstracts, STN Caesar accession number: 1146, AN 132:122591.
	C3	Cui et al. "Non-covalent Thrombin Inhibitors Featuring P ₃ -Heterocycles with P ₁ -Bicyclic Arginine Surrogates", Bioorganic & Medicinal Chemistry Letters: 12 2925-2930 (2002).
	C4	Duman, "Protein Kinase Inhibitors: Emerging Pharmacophores 1997-2001", Exp. Opin. Ther. Patents 11(3): 405-429 (2001).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.